BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35154623)

  • 1. Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents.
    Kang KW; Lee BH; Jeon MJ; Yu ES; Sik Kim D; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
    Ther Adv Hematol; 2020; 11():2040620720966882. PubMed ID: 35154623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
    Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
    Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
    Kim GYG; Burns J; Freyer CW; Hamilton KW; Frey NV; Gill SI; Hexner EO; Luger SM; Mangan JK; Martin ME; McCurdy SR; Perl AE; Porter DL; Schuster MG; Stadtmauer EA; Loren AW
    Am J Hematol; 2020 Jul; 95(7):792-798. PubMed ID: 32242967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
    Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
    Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.
    Aldoss I; Dadwal S; Zhang J; Tegtmeier B; Mei M; Arslan S; Al Malki MM; Salhotra A; Ali H; Aribi A; Sandhu K; Khaled S; Snyder D; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Blood Adv; 2019 Dec; 3(23):4043-4049. PubMed ID: 31816059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Primary antifungal prophylaxis with posaconazole plays a pivotal role during chemotherapy of acute myeloid leukemia].
    Gong BF; Liu YT; Zhang GJ; Wei SN; Li Y; Liu KQ; Gong XY; Zhao XL; Qiu SW; Gu RX; Lin D; Wei H; Zhou CL; Liu BC; Wang Y; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):528-531. PubMed ID: 28655098
    [No Abstract]   [Full Text] [Related]  

  • 8. The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent.
    Ozga M; Huang Y; Blachly JS; Grieselhuber NR; Wall S; Larkin K; Haque T; Walker AR; Bhatnagar B; Behbehani G; Vasu S; Maakaron JE; Lustberg M; Mims AS
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e76-e83. PubMed ID: 32921593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
    Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy.
    Mishra P; Agrawal N; Bhurani D; Agarwal NB
    Indian J Hematol Blood Transfus; 2020 Jan; 36(1):64-70. PubMed ID: 32174692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
    Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
    Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
    Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
    Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study.
    Shen Y; Huang XJ; Wang JX; Jin J; Hu JD; Yu K; Wu DP; Wang SJ; Yu L; Chen XQ; Liu T; Liang YM; Chen FP; Li Y; Shen ZX
    Int J Clin Pharmacol Ther; 2013 Sep; 51(9):738-45. PubMed ID: 23924680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life comparison of posaconazole versus fluconazole for primary antifungal prophylaxis during remission-induction chemotherapy for acute leukemia.
    Dufresne SF; Bergeron J; Beauchemin S; Abou Chakra CN; Vadnais B; Bouchard P; Labbé AC; Laverdière M
    J Assoc Med Microbiol Infect Dis Can; 2023 Mar; 8(1):18-28. PubMed ID: 37008582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Posaconazole Really Effective in Adolescent patients as a Prophylactic Agent: Experience of a Tertiary Care Center.
    Arikan K; Aytac S; Büyükcam A; Cengiz AB; Cetinkaya FD; Cetin M; Ozsurekci Y; Ceyhan M; Kara A
    J Pediatr Hematol Oncol; 2021 Jul; 43(5):e613-e618. PubMed ID: 33560081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
    Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
    Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
    Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies.
    Almutairy R; Khan MA; Shahbar A; Aseeri M; Alshamrani M; Almarhabi H; Naeem D
    J Oncol Pharm Pract; 2024 Apr; ():10781552241246119. PubMed ID: 38656201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
    Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
    Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.